Home 
News Releases Chambers USA Selects Stradling as One of California's Leading Life Sciences Law Firms
News Releases Chambers USA Selects Stradling as One of California's Leading Life Sciences Law Firms | Chambers USA Selects Stradling as One of California's Leading Life Sciences Law Firms |
.gif){kind=logo}
Newport Beach, CA---Stradling Yocca Carlson & Rauth and attorney Lawrence B. Cohn were selected as one of California’s leading life sciences law firms and lawyers by Chambers & Partners, the premier ranking source for law firms and attorneys. Cohn and the firm will be included in the 2009 edition of Chambers USA America’s Leading Lawyers for Business The Client’s Guide, which will be released to the public in June, 2009. About Charmber & Partners: Chambers & Partners conducts in-depth research by interviewing law firm clients, General Counsel at Fortune 100 companies, entrepreneurs and other significant purchasers of legal services to obtain a consistent perspective of which law firms and lawyers are considered leaders in their fields. The London, England-based company has been publishing legal profession guides since 1990 under the United Kingdom, USA and Global guide names. Additional information regarding Chambers & Partners, its guides and the selection process it uses to determine leading lawyers worldwide is available at www.chambersandpartners.com. About Stradling Yocca Carlson & Rauth's Life Science Practice: Stradling Yocca Carlson & Rauth’s life science practice provides sophisticated counsel to medical device, pharmaceutical and biotechnology companies at all stages of development including early-stage entrepreneurial ventures and mature, publicly traded global enterprises. The practice group assists life science clients in a variety of areas including company formation, venture capital, debt and lease financing, public offerings, securities law, executive compensation and employee incentive plans, mergers and acquisitions, technology transfer, license agreements, joint ventures and strategic alliances, among others. Recent notable transactions include: * Santen Pharmaceutical Co., Ltd.'s worldwide licensing arrangement for its ophthalmic drug Tafluprost, with Merck & Co., Inc. in April 2009 * LenSx Lasers Inc.’s $22 million Series B financing in March 2009 * Clarient Inc.’s $50 million private placement in March 2009 The firm services clients in the life sciences sector including Ista Pharmaceuticals, Clarient, Inc., Spectrum Pharmaceuticals, Inc., Questcor Pharmaceuticals, Inc., TranS1 Inc., Santen Pharmaceutical Co., Ltd., Endologix, Inc., Cell Biosciences, Inc., among others. |